Polymorphs of Selinexor
AssigneeKaryopharm Therapeutics Inc.
InventorsBrian C. Austad, David G. Roe
Life of this patent
Estimating the term…
Abstract
The present invention relates to crystalline forms of the compound represented by Structural Formula I, and compositions comprising crystalline forms of the compound represented by Structural Formula I described herein. The crystalline forms of the compound of Structural Formula I and compositions comprising the crystalline forms of the compound of Structural Formula I provided herein, in particular, single crystalline Form A, can be incorporated into pharmaceutical compositions, which can be used to treat various disorders associated with CRM1 activity, including cancer. Also described herein are methods for preparing the compound of Structural Formula I and its single crystalline forms.
Claims28
A composition, comprising particles of a single crystalline form of a compound represented by Structural Formula I:
- wherein the single crystalline form is Form A and is characterized by at least three X-ray powder diffraction peaks at 2θ angles selected from 4.4°, 19.9°, 21.3° and 22.0°;
- and
- the particles have a unimodal particle size distribution characterized by a d(0.9) of 100 microns or less.
Dependencies are inferred from the claim text.